11/3/2024

Bupivacaine with Epinephrine Injection

Products Affected - Description

- Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 10 mL vial, 50 count, NDC 00409-9042-01
- Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 30 mL vial, 100 count, NDC 00409-9042-17
- Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 50 mL vial, 25 count, NDC 00409-9043-01
- Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 10 mL vial, 50 count, NDC 00409-9045-01
- Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 30 mL vial, 100 count, NDC 00409-9045-17
- Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 50 mL vial, 25 count, NDC 00409-9046-01
- Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.25%, 10 mL vial, 25 count, NDC 63323-0468-17
- Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 10 mL vial, 25 count, NDC 63323-0462-17
- Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 30 mL vial, 25 count, NDC 63323-0462-37

Reason for the Shortage

- Fresenius Kabi has bupivacaine and epinephrine on shortage due to increased demand.
- Pfizer has bupivacaine with epinephrine on shortage due to manufacturing delays.

Available Products

- Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 10 mL vial, 10 count, NDC 00409-1746-10
- Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 30 mL vial, 10 count, NDC 00409-1746-30
- Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 50 mL vial, 1 count, NDC 00409-1752-50
- Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 10 mL vial, 10 count, NDC 00409-1749-10
- Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 30 mL vial, 10 count, NDC 00409-1749-29
- Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 50 mL vial, 1 count, NDC 00409-1755-50
- Sensorcaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.25%, 50 mL vial, 25 count, NDC 63323-0461-57
- Sensorcaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 50 mL vial, 25 count, NDC 63323-0463-57
- Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.25%, 30 mL vial, 25 count, NDC 63323-0468-37
- Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.75%, 30 mL vial, 25 count, NDC 63323-0460-37

Estimated Resupply Dates

- Pfizer has 0.25% bupivacaine with epinephrine 10 mL and 30 mL preservative-free vials on back order and the company estimates a release date of June 2025. The 0.25% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of June 2025. The 0.5% bupivacaine with epinephrine 10 mL and 30 mL preservative-free vials are on back order and the company estimates a release date of June 2025. The 0.5% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of April 2025.
- Fresenius Kabi has short-dated 0.25% Sensorcaine 10 mL preservative-free vials available with an expiration date of < 9 months. There are short-dated 0.5% Sensorcaine 10 mL and 30 mL preservative-free vials available with an expiration date of < 9 months.

Updated

Updated November 3, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 2, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.